Effect of ropinirole hydrochloride in progressive myoclonic epilepsy of Unverricht–Lundborg type

• Conditions: Progressive myoclonus epilepsy of the Unverricht–Lundborg disease (ULD) type; MedDRA version: 9.1Level: PTClassification code 10054895Term: Baltic myoclonic epilepsy

• Registration Number: EUCTR2007-003210-33-FI
• Lead Sponsor: Department of Neurology, Turku University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-06-13
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

1) ULD diagnosed by an experienced neurologist, and confirmed with molecular diagnostics
2) Stimulus-activated myoclonus as the most prominent symptom of ULD
3) Age 18-60 years

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years)
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years)
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1) Current medicated psychiatric disorder
2) Previous severe head trauma
3) History of alcohol/substance abuse
4) Pregnancy or lactation
5) Known hypersensitivity to ropinirole hydrochloride or to other ingredients of the product
6) Concomitant participation in another drug study
7) Severe renal or hepatic insufficiency

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified